Cost is not a barrier to implementing clopidogrel pharmacogenetics.

Pharmacogenetics in Practice Pharmacogenetics in Cardiology: Forays into Modern Practice

When one discusses pharmacogenetics in cardiology practice, it is almost obligatory to discuss clopidogrel. Clopidogrel is an antiplatelet used for acute coronary syndrome (ACS), percutaneous coronary intervention (PCI) with stenting, and as secondary stroke prevention in patients with aspirin allergy, among other indications. Clopidogrel is a prodrug that must be metabolized through the cytoch...

Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy.

The Personalization of Clopidogrel Antiplatelet Therapy: The Role of Integrative Pharmacogenetics and Pharmacometabolomics

Dual antiplatelet therapy of aspirin and clopidogrel is pivotal for patients undergoing percutaneous coronary intervention. However, the variable platelets reactivity response to clopidogrel may lead to outcome failure and recurrence of cardiovascular events. Although many genetic and nongenetic factors are known, great portion of clopidogrel variable platelets reactivity remain unexplained whi...

Barrier of implementing non-pharmacological pain management in children and presented intereventions by nurses

  Introduction : Researches indicate that children's pain is still not managed well. Pain relief with non pharmaceutical methods in addition to being cost effective it is uninvasive and it only depends on nurses' performance.   Objective: This study aims to determine important barriers and presented interventions by nurses for non pharmaceutical pain management in children. &nbs...

Investigating Real‐World Clopidogrel Pharmacogenetics in Stroke Using a Bioresource Linked to Electronic Medical Records

Clopidogrel efficacy is influenced by genetic variation of cytochrome P450 (CYP)2C19, however, few studies have considered patients who have a stroke. We used electronic medical records (EMRs) linked to a bioresource to examine real-world implications of clopidogrel pharmacogenetics in stroke. Patients hospitalized for any arterial thrombo-occlusive (ATO) event who subsequently redeemed clopido...